Open access · OA
via OpenAlex
Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine
Neeraj Kumar Satija, Vimal Kishor Singh, Yogesh Kumar Verma, Pallavi Gupta, Shilpa Sharma, Farhat Afrin, Menka Sharma, Pratibha Sharma, R. P. Tripathi, G. U. Gurudutta
Journal of Cellular and Molecular Medicine · 2009 · ▲ 252 citations
Abstract
Mesenchymal stem cells (MSCs), adherent fibroblastoid cells, present in bone marrow and many other tissues can be easily isolated and expanded in vitro. They are capable of differentiating into different cell types such as osteoblasts, chondrocytes, adipocytes, cardiomyocytes, hepatocytes, endothelial cells and neuronal cells. Such immense plasticity coupled with their ability to modulate the activity of immune cells makes them attractive for stem cell-based therapy aimed at treating previously incurable disorders. Preclinical studies have reported successful use of MSCs for delivering therapeutic proteins and repairing defects in a variety of disease models. These studies highlighted the in vivo potential of MSCs and their ability to home to injury sites and modify the microenvironment by secreting paracrine factors to augment tissue repair. Their therapeutic applicability has been widened by genetic modification to enhance differentiation and tissue targeting, and use in tissue engineering. Clinical trials for diseases such as osteogenesis imperfecta, graft-versus-host disease and myocardial infarction have shown some promise, demonstrating the safe use of both allogeneic and autologous cells. However, lack of knowledge of MSC behaviour and responses in vitro and in vivo force the need for basic and animal studies before heading to the clinic. Contrasting reports on immunomodulatory functions and tumorigenicity along with issues such as mode of cell delivery, lack of specific marker, low survival and engraftment require urgent attention to harness the potential of MSC-based therapy in the near future.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/j.1582-4934.2009.00857.x
- Canonical
- link ↗
- Fetched
- 2026-09-28 MST
Cite this
APA
Satija, N.K., Singh, V.K., Verma, Y.K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R.P., & Gurudutta, G.U. (2009). Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine. <em>Journal of Cellular and Molecular Medicine</em>. https://doi.org/10.1111/j.1582-4934.2009.00857.x
Vancouver
Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, et al. Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine. Journal of Cellular and Molecular Medicine. 2009. doi:10.1111/j.1582-4934.2009.00857.x.
BibTeX
@article{neeraj2009Mesenc,
title = {Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine},
author = {Neeraj Kumar Satija and Vimal Kishor Singh and Yogesh Kumar Verma and Pallavi Gupta and Shilpa Sharma and Farhat Afrin and Menka Sharma and Pratibha Sharma and R. P. Tripathi and G. U. Gurudutta},
journal = {Journal of Cellular and Molecular Medicine},
year = {2009},
doi = {10.1111/j.1582-4934.2009.00857.x},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Expert Opinion on Biological Therapy 2023
Preprint · OA
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells
Stem Cell Research & Therapy 2025
Open access · CC-BY
Advances in mesenchymal stem cell and exosome-based therapies for aging and age-related diseases
Korean journal of family medicine 2025
Open access · OA
Systemic aging delay and anti-aging therapy using allogeneic stem cells.
PubMed 2001
Preprint
[Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis].
Frontiers in Medicine 2018
Open access · CC-BY
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Frontiers in Bioengineering and Biotechnology 2020
Open access · CC-BY